REG - AstraZeneca PLC - Enhertu approved in EU for HER2-positive eBC

What happened

AstraZeneca and Daiichi Sankyo's Enhertu was approved in the European Union as an adjuvant, or post-surgery, treatment for adults with resected HER2-positive early breast cancer who have leftover invasive disease after initial treatment. The DESTINY-Breast05 Phase III trial showed a 53% lower risk of invasive disease return or death versus T-DM1.

Confirmed

Global impact / market context

This is Enhertu's first EU approval in early breast cancer treated with curative intent, which means aiming to cure rather than only control the disease. That opens a new patient group before cancer returns, supporting wider use and potentially more revenue for AstraZeneca and Daiichi Sankyo.

Analyst inference

Breast cancer treatment is a large, competitive drug area, and moving into earlier-stage disease can expand use beyond patients whose cancer has already spread. For investors, the approval adds a new commercial setting, but uptake will depend on doctor adoption, reimbursement decisions and how the trial's survival benefits are viewed.

Analyst inference

What to watch

1. Watch how European regulators and health systems decide reimbursement, which means whether public or insurer budgets will pay for Enhertu in this earlier setting, since that determines actual patient access. Confirmed
2. Track whether doctors adopt the drug broadly in adjuvant use, because prescribing habits in early breast cancer, where patients hope to be cured, can move slowly even after approval. Analyst inference
3. Monitor sales updates from AstraZeneca and Daiichi Sankyo for signs this new EU label meaningfully adds revenue, since the article gives no prices, patient numbers or launch timing. Analyst inference

Evidence

• Original source link unavailable